InvestorsHub on MSN

Maze Therapeutics shares surge after positive Phase 2 data for MZE829

Maze Therapeutics Inc. (NASDAQ:MAZE) reported a fourth-quarter loss of $0.65 per share on Wednesday, while also announcing ...
Investor's Business Daily on MSN

Why Maze Therapeutics Plunged 20%-Plus Despite 'Overwhelming Positive' Data

Maze Therapeutics stock crashed Wednesday despite "overwhelmingly positive" test results for a kidney disease drug.
Fierce Biotech

After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets

Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its ...

Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%

This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider sale.

Maze Therapeutics Shares Phase II HORIZON Data: MZE829 Cuts Proteinuria in APOL1 Kidney Disease

Maze Therapeutics (NASDAQ:MAZE) outlined positive Phase II results from its open-label HORIZON study evaluating MZE829 in ...
BioSpace

Maze Loses Nearly a Third of Market Share on Mixed Midstage Kidney Drug Data

Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung ...
BioPharma Dive

Maze tumbles on positive data for kidney disease drug

Investors had reservations over data from Maze for a drug that could compete with a candidate from Vertex in a ...

Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears

This pharmaceutical company's executive sold all his direct shares less than a month before a highly anticipated earnings ...
Investing.com Canada

Maze Therapeutics stock soars 22% on positive trial data for MZE829

Maze Therapeutics Inc. (NASDAQ:MAZE) reported a fourth quarter loss of $0.65 per share on Wednesday, following positive Phase 2 trial results for its lead dr ...